Does a positive anti-CCP test identify a distinct arthritis entity?

Arthritis Research and Therapy

Volumn 7, Issue 6, 2005, Pages 230-232

  Skogh, Thomas ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMALARIAL AGENT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ANTIBODY DETECTION; ANTIBODY TITER; CIGARETTE SMOKING; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FOLLOW UP; HEREDITY; HUMAN; IMMUNIZATION; IMMUNOASSAY; LATEX AGGLUTINATION TEST; NONHUMAN; NOTE; PATHOGENESIS; PHENOTYPE; PREDICTION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; HUMANS; PEPTIDES, CYCLIC; RHEUMATOLOGY;

EID: 27844552551     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1836     Document Type: Note

References (11)

1. van der Heim-van Mil AHM, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958.
2. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJM, van Venrooij WJ: Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004, 350:17-34.
3. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L: A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50:3085-3092.
4. Linn-Rasker SP, van der Helm-van Mil AHM, van Gaalen FA, Klop-penburg M, De Vries R, le Cessie S, Breedveld FC, Toes REM, Huizinga TWJ: Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2005 [Epub ahead of print].
5. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides; (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095.
6. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E: Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171:538-541.
7. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR: A combination of autoantibodies; to cyclic citrullinated peptide (CCP) and HLA-DRB31 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R303-R308.
8. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grünewald J, Rönnelid J, Erlandsson Harris H, Ulfgren AK, Rantapää-Dahlqvist S, et al.: A new model for an etiology of RA: smoking may trigger HLA-DR (SE)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2005, in press.
9. Kastbom A, Strandberg G, Lindroos A, Skogh T: Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089.
10. Rönnelid J, Wick MC, Lampa. J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven R: Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005 [Epub ahead of print].
11. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004, 50:3776-3782.